Perioperative use of ceftazidime as a prophylactic agent in transurethral surgery.
Sixty-eight patients undergoing transurethral surgery were randomly assigned to receive either a single dose of ceftazidime (31 patients) preoperatively, or three doses of cefotaxime (34 patients) perioperatively, as prophylaxis. In this study, only 1/20 male patients (5%), and none of the female patients, developed an infection. We conclude that single-dose prophylaxis, with a safe, broad-spectrum antimicrobial, provides adequate protection against postoperative infection in genitourinary surgery.
D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000627:therapeutic use; D002442:Ceftazidime; D002511:Cephalosporins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D011897:Random Allocation; D013530:Surgical Wound Infection / Q000517:prevention & control*; D014521:Urethra / Q000601:surgery; D014566:Urogenital System / Q000601:surgery*
D002511:Cephalosporins; D002442:Ceftazidime; D002439:Cefotaxime